TriSalus Life Sciences, Inc.
$4.8M 2,429 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Novocure GmbH
Novocure GmbH reported $4,770,986.25 across General Payments, Research, and Ownership to 7 physicians and teaching hospitals across 608 transactions.
- $4.8M Top quartile payer
- All-tracks total
- 608 Above-median volume
- Transactions
- 7 Below-median reach
- Recipients
- −$151.8K
- General Payments vs PY2023
Novocure GmbH reported $4,770,986.25 across all CMS Open Payments tracks (General + Research + Ownership) to 7 physicians and teaching hospitals in Program Year 2024 - ranking #285 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $19,143.58, averaging $681.6K per recipient.
How Novocure GmbH's $4.8M all-tracks total breaks down
Novocure GmbH's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
32/100
Total payments
D
54/100
Transaction volume
F
14/100
Physician reach
F
10/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer novocure-gmbh Novocure GmbH
$4.8M · #285/1,925 · 0.0% industry · PY2024
- TOT $4.8M
- RANK #285
- SHARE 0.0%
- TXN 608
- RCP 7
- CAT 4
- GEN $19.1K
- ΔGEN −$151.8K
- TOP1 78.4%
- PY 2024
Volume peers
Nearest volume peer: TriSalus Life Sciences, Inc. ($4.8M)
Novocure GmbH sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Novocure GmbH's CMS-reported General Payments decreased by $151.8K (−88.8%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: NOVOCURE GMBHPY2023: NOVOCURE GMBHPY2024: Novocure GmbH. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $170,961.29
- PY2024
- $19,143.58
What the Data Shows for Novocure GmbH
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Novocure GmbH, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
3 transactions worth $15.0K make "Consulting Fee" the top general-payment category in the 4-category breakdown below, 78.4% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Consulting Fee" leads Novocure GmbH's 4-category general-payment breakdown at $15.0K, 78.4% of the reported total.
Novocure GmbH reports 4 general-payment categories - the top three are Consulting Fee (78.4%), Honoraria (18.3%), and Travel and Lodging (3.2%). The remaining 1 category make up 0.2% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Novocure GmbH divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $15.0K | 3 | 78.4% |
| Honoraria | $3.5K | 1 | 18.3% |
| Travel and Lodging | $603.22 | 1 | 3.2% |
| Food and Beverage | $40.36 | 2 | 0.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $19,143.58 (100.0%) of $19,143.58 in this company's General Payments records across 3 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Novocure GmbH
The five named recipients with the highest reported General Payments from this company
- 1
Steven A Toms
$15,000.00 across 3 reported transactions
- 2
Sami Diab
$3,500.00 across 1 reported transactions
- 3
Rupesh Rajesh Kotecha
$643.58 across 3 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Novocure GmbH's spend rank (#285 of 1,925, top 15% by spend) and concentration rank (#246 of 1,838, top 13% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Esteve Pharmaceuticals LLC : $93.5K total payments, HHI 6597
- Philadelphia Medical Management Company LLC : $174.9K total payments, HHI 6579
- Bernhard Foerster GmbH : $347.7K total payments, HHI 6541
- Helios Cardio Inc : $17.4K total payments, HHI 6534
- Instrumentation Laboratory Company : $1.4M total payments, HHI 6528
- KARL STORZ SE & Co. KG : $39.6K total payments, HHI 6505
- Novocure GmbH (this company) : $19.1K total payments, HHI 6485
- Prolaio, Inc. : $8.5K total payments, HHI 6466
- Catalent Pharma Solutions, LLC : $6.3K total payments, HHI 6454
- Dutch Ophthalmic Research Center (International) B.V. : $12.1K total payments, HHI 6407
- Sealonix Inc. : $44.9K total payments, HHI 6380
- Purdue Pharmaceuticals L.P. : $248.5K total payments, HHI 6374
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Novocure GmbH's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Novocure GmbH.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Novocure GmbH.
Showing 6 of 1,924 companies with CMS-reported payment data.
Progenics Pharmaceuticals, Inc.
$4.8M 6,457 recipients
Compare payment profiles
Stemline Therapeutics Inc.
$4.7M 6,314 recipients
Compare payment profiles
Inspire Medical Systems, Inc.
$4.8M 51,283 recipients
Compare payment profiles
InSightec,LTD
$4.9M 2 recipients
Compare payment profiles
Blustone Synergy, LLC
$4.9M 0 recipients
Compare payment profiles
Put this to use
Novocure GmbH ranks #285 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Novocure GmbH sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Novocure GmbH. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.